(BFM Bourse) – The Toulouse biotechnology company announced new results for its phase 2a study evaluating CER-001 in sepsis. Promising scientific results could also facilitate the conclusion of partnerships, according to TP ICAP Midcap.
The biotech Abionyx, which was still called Cerenis until the summer of 2019, communicated preclinical data for its flagship molecule at a scientific conference in Italy.
These are new results from the Racers phase 2a study (intermediate stage of clinical trials, which evaluates the effectiveness of a drug), carried out in Italy and evaluating the group’s largest molecule, CER-001, in sepsis, a serious condition better known as sepsis.
It is characterized by a generalized infection caused by bacteria in the blood. And some people can even experience acute kidney failure, which can be accompanied by brain dysfunction, called Brain Frog or brain fog.
Abionyx reminds that to date there are no appropriate preventive or therapeutic solutions to treat brain dysfunctions, called Brain Frog or brain fog, linked to kidney damage resulting from or concomitant with sepsis.
“Beyond the reduction in mortality of septic patients treated with the CER-001 molecule, and the reduction in the length of hospitalization, the Racers study helped to highlight a potential improvement in the renal functions of patients and cognitive functions”, specifies TP ICAP Midcap in its note dedicated to these new results of this study carried out in Italy.
Other indications for CER-001
In light of these clinical results, Professor Loreto Gesualdo, who led the study in Italy, plans to extend the clinical development of CER-001 into potential new indications affecting the gut-kidney-brain axis.
“Together, these data indicate that treatment with CER-001 can decrease the inflammatory response, retention of residual substances and neuroactive compounds, thereby potentially improving the status of renal and cognitive functions in renal failure. acute sepsis-induced. These results open the way to future clinical studies in potential additional indications, such as neuropsychiatric lupus or, more importantly, long Covid,” explains Abionyx.
The financial intermediary believes that these results “could also facilitate the conclusion of partnerships which will prove necessary for the continuation of clinical studies in the areas already addressed (phase III for sepsis, phase I for the ophthalmological field) but also in new indications”.
The scientific results presented by Abionyx Pharma should “continue to feed the newsflow on the title, pending the signing of partnerships, and the approval phases of future treatments”, explains TP ICAP Midcap, which also reiterated its buying advice and its price target of 10.5 euros.
On the Paris Stock Exchange, the market appreciates Abionyx Pharma’s latest milestone. The stock rose 4% to 1.23 euros around 5:05 p.m.
Sabrina Sadgui – ©2023 BFM Bourse
Are you following this action?
Receive all the information on ABIONYX PHARMA in real time: